DARE - Dare Bioscience, Inc.
IEX Last Trade
3.21
-0.130 -4.050%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$3.34
-0.13
-3.89%
Fundamental analysis
23%
Profitability
25%
Dept financing
17%
Liquidity
50%
Performance
15%
Performance
5 Days
18.08%
1 Month
0.63%
3 Months
-2.87%
6 Months
-38.34%
1 Year
-19.19%
2 Year
-69.35%
Key data
Stock price
$3.21
DAY RANGE
$3.21 - $3.34
52 WEEK RANGE
$2.93 - $7.56
52 WEEK CHANGE
-$21.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Sabrina M. Johnson
Region: US
Website: darebioscience.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: darebioscience.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Daré Bioscience, Inc. develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive.
Recent news